DK2417158T4 - Dkk-1-antistoffer - Google Patents

Dkk-1-antistoffer

Info

Publication number: DK2417158T4
Authority: DK; Denmark
Prior art keywords: dkk; antibodies; human; pathogenesis; antigen
Prior art date: 2009-04-10

Application number

DK10712681.5T

Other languages

English (en)

Other versions

DK2417158T3 (da

Inventor

Marcio Chedid

Ryan James Darling

Rachelle Jeanette Galvin

Barbara Anne Swanson

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-04-10

Filing date

2010-04-06

Publication date

2018-01-29

2010-04-06 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2017-10-16 Application granted granted Critical

2017-10-16 Publication of DK2417158T3 publication Critical patent/DK2417158T3/da

2018-01-29 Publication of DK2417158T4 publication Critical patent/DK2417158T4/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Bioinformatics & Cheminformatics (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Epidemiology (AREA)
Oncology (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Microbiology (AREA)
Mycology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

DK10712681.5T 2009-04-10 2010-04-06 Dkk-1-antistoffer DK2417158T4 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US16841109P	2009-04-10	2009-04-10
PCT/US2010/030039 WO2010117980A1 (en)	2009-04-10	2010-04-06	Dkk-1 antibodies

Publications (2)

Publication Number	Publication Date
DK2417158T3 DK2417158T3 (da)	2017-10-16
DK2417158T4 true DK2417158T4 (da)	2018-01-29

Family

ID=42199718

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
DK19156509.2T DK3514173T3 (da)	2009-04-10	2010-04-06	DKK-1-antistoffer
DK15159780.4T DK2930184T3 (da)	2009-04-10	2010-04-06	Dkk-1-antistoffer
DK10712681.5T DK2417158T4 (da)	2009-04-10	2010-04-06	Dkk-1-antistoffer

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
DK19156509.2T DK3514173T3 (da)	2009-04-10	2010-04-06	DKK-1-antistoffer
DK15159780.4T DK2930184T3 (da)	2009-04-10	2010-04-06	Dkk-1-antistoffer

Country Status (30)

Country	Link
US (1)	US8148498B2 (da)
EP (3)	EP3514173B8 (da)
JP (1)	JP5759977B2 (da)
KR (3)	KR20110124364A (da)
CN (1)	CN102388065B (da)
AR (1)	AR075989A1 (da)
AU (1)	AU2010234611B2 (da)
BR (1)	BRPI1014157B1 (da)
CA (1)	CA2758252C (da)
CY (3)	CY1119399T1 (da)
DK (3)	DK3514173T3 (da)
EA (1)	EA021401B1 (da)
ES (3)	ES2728911T3 (da)
HR (3)	HRP20171400T1 (da)
HU (3)	HUE043904T2 (da)
IL (1)	IL214845A (da)
LT (3)	LT3514173T (da)
ME (2)	ME02798B (da)
MX (1)	MX2011010707A (da)
NZ (1)	NZ595011A (da)
PL (3)	PL2417158T3 (da)
PT (3)	PT2417158T (da)
RS (3)	RS58612B1 (da)
SG (1)	SG175244A1 (da)
SI (3)	SI2930184T1 (da)
TR (1)	TR201907261T4 (da)
TW (1)	TWI546079B (da)
UA (1)	UA103916C2 (da)
WO (1)	WO2010117980A1 (da)
ZA (1)	ZA201107256B (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR076668A1 (es)	2009-05-12	2011-06-29	Pfizer	Anticuerpos especificos para dkk-1 y sus usos
EP3686218A1 (en)	2012-12-10	2020-07-29	Biogen MA Inc.	Anti-blood dendritic cell antigen 2 antibodies and uses thereof
BR112017020610A2 (pt)	2015-05-18	2018-07-17	Lilly Co Eli	Compostos de anticorpo biespecífico anti-dkk-1- anti-rankl
CA2996059A1 (en) *	2015-08-28	2017-03-09	Alector Llc	Anti-siglec-7 antibodies and methods of use thereof
WO2017079116A2 (en)	2015-11-03	2017-05-11	Janssen Biotech, Inc.	Antibodies specifically binding pd-1 and tim-3 and their uses
MX2019004940A (es)	2016-10-26	2019-09-26	Leap Therapeutics Inc	Uso de beta-catenina como un biomarcador para el tratamiento de canceres que usan el anticuerpo anti-dkk-1.
MX2021000306A (es) *	2018-07-11	2021-09-08	Momenta Pharmaceuticals Inc	Composiciones y métodos relacionados con constructos de dominio de unión a antígeno y fc modificados genéticamente dirigidos a ctla-4.
CN112121147B (zh) *	2019-06-24	2023-07-04	中国人民解放军海军特色医学中心	多肽在治疗或预防骨髓瘤药物中的应用、多肽、核酸、药物及重组表达载体
AU2020348457A1 (en)	2019-09-19	2022-04-07	Leap Therapeutics, Inc.	Use of DKK-1 inhibitors for treating cancer
AU2020386091A1 (en) *	2019-11-22	2022-06-09	Leap Therapeutics, Inc.	Methods of treating cancer using DKK-1-inhibitors
KR102494042B1 (ko) *	2020-11-20	2023-02-07	주식회사 하울바이오	인간모유두세포의 성장을 촉진하는 항-dkk-1 항체 및 이의 용도
CN112592402B (zh) *	2020-12-02	2022-04-26	杭州奕安济世生物药业有限公司	抗dkk2抗体、包含该抗dkk2抗体的组合物及其用途
WO2022170090A1 (en) *	2021-02-05	2022-08-11	Omeros Corporation	Biomarker for assessing the risk of developing acute covid-19 and post-acute covid-19
EP4398889A1 (en)	2021-09-10	2024-07-17	Leap Therapeutics, Inc.	Combination therapy
AU2023308189A1 (en)	2022-07-12	2025-01-23	Leap Therapeutics, Inc.	Combination therapy
CN116589590B (zh) *	2023-03-21	2024-03-26	浙江大学	一种特异性抗异菌脲的单克隆抗体及其重组表达质粒

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8308235D0 (en)	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
WO1999046281A2 (en)	1998-03-10	1999-09-16	Genentech, Inc.	Novel polypeptides and nucleic acids encoding the same
PT975755E (pt)	1997-04-16	2007-06-26	Millennium Pharm Inc	Proteínas crsp (proteínas segregadas ricas em cisteínas), moléculas de ácido nucleico que as codificam e suas utilizações
DE19747418C1 (de)	1997-10-27	1999-07-15	Deutsches Krebsforsch	Inhibitor-Protein des wnt-Signalwegs
US7446181B2 (en) *	1998-01-15	2008-11-04	Millennium Pharmaceuticals, Inc.	Antibodies that bind human Dickkopf-1 proteins
EP1572987A4 (en)	2000-02-03	2005-11-30	Nuvelo Inc	NUCLEIC ACIDS AND POLYPEPTIDES
WO2002083921A2 (en)	2001-04-10	2002-10-24	Agensys, Inc.	Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers
US20040038860A1 (en) *	2002-05-17	2004-02-26	Allen Kristina M.	Reagents and methods for modulating dkk-mediated interactions
EP1395285A4 (en)	2001-05-17	2005-06-01	Genome Therapeutics Corp	REAGENTS AND METHODS FOR MODULATING INDUCED DKK INTERACTIONS
US7371736B2 (en) *	2001-11-07	2008-05-13	The Board Of Trustees Of The University Of Arkansas	Gene expression profiling based identification of DKK1 as a potential therapeutic targets for controlling bone loss
US7308364B2 (en) *	2001-11-07	2007-12-11	The University Of Arkansas For Medical Sciences	Diagnosis of multiple myeloma on gene expression profiling
MXPA04004378A (es)	2001-11-07	2004-09-10	Univ Arkansas	Diagnostico, prognosis e identificacion de objetivos terapeuticos potenciales de mieloma multiple basado en el perfilado de expresion de genes.
US7642238B2 (en) *	2002-12-05	2010-01-05	Shaughnessy John D	Molecular determinants of myeloma bone disease and uses thereof
US20050084494A1 (en) *	2003-05-21	2005-04-21	Darwin Prockop	Inhibitors of Dkk-1
MXPA05013115A (es)	2003-06-06	2006-05-25	Wyeth Corp	Metodos y materiales para identificar agentes que modulan la remodelacion de hueso y agentes identificados por los mismos.
MX2007001221A (es) *	2004-08-04	2007-03-23	Amgen Inc	Anticuerpos para proteina dickkopf-1 (dkk-1).
AR060017A1 (es) *	2006-01-13	2008-05-21	Novartis Ag	Composiciones y metodos de uso para anticuerpos de dickkopf -1
WO2008097510A1 (en) *	2007-02-08	2008-08-14	Merck & Co., Inc.	Antibodies specific for dkk-1
CA2759078A1 (en) *	2009-05-07	2010-11-11	Novartis Ag	Compositions and methods of use for binding molecules to dickkopf-1 or dickkopf-4 or both

2010
- 2010-03-29 AR ARP100101019A patent/AR075989A1/es active IP Right Grant
- 2010-04-02 TW TW099110438A patent/TWI546079B/zh active
- 2010-04-06 EP EP19156509.2A patent/EP3514173B8/en active Active
- 2010-04-06 ES ES15159780T patent/ES2728911T3/es active Active
- 2010-04-06 PL PL10712681T patent/PL2417158T3/pl unknown
- 2010-04-06 HU HUE15159780A patent/HUE043904T2/hu unknown
- 2010-04-06 UA UAA201111272A patent/UA103916C2/ru unknown
- 2010-04-06 PT PT107126815T patent/PT2417158T/pt unknown
- 2010-04-06 US US12/754,637 patent/US8148498B2/en active Active
- 2010-04-06 EA EA201171237A patent/EA021401B1/ru not_active IP Right Cessation
- 2010-04-06 ME MEP-2017-212A patent/ME02798B/me unknown
- 2010-04-06 RS RS20190470A patent/RS58612B1/sr unknown
- 2010-04-06 SI SI201031877T patent/SI2930184T1/sl unknown
- 2010-04-06 HU HUE10712681A patent/HUE034625T2/en unknown
- 2010-04-06 CN CN201080015994.4A patent/CN102388065B/zh active Active
- 2010-04-06 SI SI201032080T patent/SI3514173T1/sl unknown
- 2010-04-06 PT PT15159780T patent/PT2930184T/pt unknown
- 2010-04-06 KR KR1020117023571A patent/KR20110124364A/ko not_active Application Discontinuation
- 2010-04-06 EP EP10712681.5A patent/EP2417158B9/en active Active
- 2010-04-06 MX MX2011010707A patent/MX2011010707A/es active IP Right Grant
- 2010-04-06 SG SG2011075579A patent/SG175244A1/en unknown
- 2010-04-06 ME MEP-2019-98A patent/ME03378B/me unknown
- 2010-04-06 JP JP2012504760A patent/JP5759977B2/ja active Active
- 2010-04-06 EP EP15159780.4A patent/EP2930184B1/en active Active
- 2010-04-06 DK DK19156509.2T patent/DK3514173T3/da active
- 2010-04-06 AU AU2010234611A patent/AU2010234611B2/en active Active
- 2010-04-06 LT LTEP19156509.2T patent/LT3514173T/lt unknown
- 2010-04-06 SI SI201031526T patent/SI2417158T1/sl unknown
- 2010-04-06 PL PL15159780T patent/PL2930184T3/pl unknown
- 2010-04-06 RS RS20210998A patent/RS62214B1/sr unknown
- 2010-04-06 RS RS20170959A patent/RS56505B1/sr unknown
- 2010-04-06 PT PT191565092T patent/PT3514173T/pt unknown
- 2010-04-06 NZ NZ595011A patent/NZ595011A/xx unknown
- 2010-04-06 LT LTEP15159780.4T patent/LT2930184T/lt unknown
- 2010-04-06 ES ES10712681.5T patent/ES2644244T3/es active Active
- 2010-04-06 PL PL19156509T patent/PL3514173T3/pl unknown
- 2010-04-06 KR KR1020147018130A patent/KR20140090273A/ko not_active Application Discontinuation
- 2010-04-06 KR KR1020147005305A patent/KR101461362B1/ko active IP Right Grant
- 2010-04-06 DK DK15159780.4T patent/DK2930184T3/da active
- 2010-04-06 LT LTEP10712681.5T patent/LT2417158T/lt unknown
- 2010-04-06 TR TR2019/07261T patent/TR201907261T4/tr unknown
- 2010-04-06 ES ES19156509T patent/ES2887176T3/es active Active
- 2010-04-06 CA CA2758252A patent/CA2758252C/en active Active
- 2010-04-06 HU HUE19156509A patent/HUE055376T2/hu unknown
- 2010-04-06 DK DK10712681.5T patent/DK2417158T4/da active
- 2010-04-06 WO PCT/US2010/030039 patent/WO2010117980A1/en active Application Filing
- 2010-04-06 BR BRPI1014157-0A patent/BRPI1014157B1/pt active IP Right Grant
2011
- 2011-08-25 IL IL214845A patent/IL214845A/en active IP Right Grant
- 2011-10-04 ZA ZA2011/07256A patent/ZA201107256B/en unknown
2017
- 2017-09-15 HR HRP20171400TT patent/HRP20171400T1/hr unknown
- 2017-09-29 CY CY20171101022T patent/CY1119399T1/el unknown
2019
- 2019-04-03 HR HRP20190643TT patent/HRP20190643T1/hr unknown
- 2019-05-17 CY CY20191100531T patent/CY1121637T1/el unknown
2021
- 2021-08-06 CY CY20211100700T patent/CY1124412T1/el unknown
- 2021-08-20 HR HRP20211343TT patent/HRP20211343T1/hr unknown

Also Published As

Publication number	Publication date
CA2758252A1 (en)	2010-10-14
LT2417158T (lt)	2017-10-10
PL3514173T3 (pl)	2022-01-17
TR201907261T4 (tr)	2019-06-21
EP2417158A1 (en)	2012-02-15
EA021401B1 (ru)	2015-06-30
CA2758252C (en)	2015-02-24
EP3514173B1 (en)	2021-06-23
EP2930184A1 (en)	2015-10-14
IL214845A (en)	2016-06-30
NZ595011A (en)	2013-05-31
ES2728911T3 (es)	2019-10-29
PT2930184T (pt)	2019-06-17
CN102388065A (zh)	2012-03-21
CY1121637T1 (el)	2020-07-31
EP3514173B8 (en)	2021-08-04
KR101461362B1 (ko)	2014-11-13
DK3514173T3 (da)	2021-08-02
UA103916C2 (xx)	2013-12-10
EA201171237A1 (ru)	2012-04-30
DK2417158T3 (da)	2017-10-16
CY1119399T1 (el)	2018-02-14
RS58612B1 (sr)	2019-05-31
HRP20211343T1 (hr)	2021-11-26
ME03378B (me)	2020-01-20
PT2417158T (pt)	2017-10-23
RS62214B1 (sr)	2021-09-30
AR075989A1 (es)	2011-05-11
HRP20171400T1 (hr)	2017-11-03
US20100260754A1 (en)	2010-10-14
SI2417158T1 (sl)	2017-10-30
MX2011010707A (es)	2012-02-28
CN102388065B (zh)	2014-09-03
HUE034625T2 (en)	2018-02-28
KR20140090273A (ko)	2014-07-16
HUE043904T2 (hu)	2019-09-30
EP2930184B1 (en)	2019-03-27
KR20140033523A (ko)	2014-03-18
JP2012523417A (ja)	2012-10-04
TW201100101A (en)	2011-01-01
LT3514173T (lt)	2021-09-10
BRPI1014157A2 (pt)	2020-09-29
PL2930184T3 (pl)	2019-10-31
ZA201107256B (en)	2013-03-27
ES2887176T3 (es)	2021-12-22
TWI546079B (zh)	2016-08-21
SI2930184T1 (sl)	2019-06-28
PL2417158T3 (pl)	2017-12-29
KR20110124364A (ko)	2011-11-16
HRP20190643T1 (hr)	2019-05-31
SI3514173T1 (sl)	2021-09-30
DK2930184T3 (da)	2019-05-13
PT3514173T (pt)	2021-08-16
CY1124412T1 (el)	2022-07-22
RS56505B1 (sr)	2018-02-28
BRPI1014157B1 (pt)	2022-01-18
EP2417158B9 (en)	2017-12-06
SG175244A1 (en)	2011-12-29
HUE055376T2 (hu)	2021-11-29
AU2010234611B2 (en)	2013-02-07
EP2417158B1 (en)	2017-08-02
IL214845A0 (en)	2011-11-30
EP3514173A1 (en)	2019-07-24
JP5759977B2 (ja)	2015-08-05
US8148498B2 (en)	2012-04-03
ES2644244T3 (es)	2017-11-28
WO2010117980A1 (en)	2010-10-14
ME02798B (me)	2018-01-20
LT2930184T (lt)	2019-05-10
AU2010234611A1 (en)	2011-10-20

Publication	Publication Date	Title
DK2417158T4 (da)	2018-01-29	Dkk-1-antistoffer
JO3097B1 (ar)	2017-03-15	الأجسام المضادة c-Met
PH12012501761A1 (en)	2012-11-12	Anti-nerve growth factor (ngf) antibody compositions
EA201291336A1 (ru)	2013-04-30	Замещенные 5-фтор-1н-пиразолопиридины и их применение
UA109658C2 (xx)	2015-09-25	Антитіло проти cgrp
EA201370081A1 (ru)	2013-12-30	Антитела к cd48 и их применение
PH12012502523A1 (en)	2013-02-11	Dual variable domain immunoglobulins and uses thereof
WO2010032059A3 (en)	2010-06-24	Antibodies directed to cd105 and uses thereof
EA201390060A1 (ru)	2013-07-30	Аннелированные пиримидины и триазины и их применение для лечения и/или профилактики сердечно-сосудистых заболеваний
EA201270662A1 (ru)	2013-01-30	Связывающие элементы для человеческого цитамегаловируса
WO2012109373A3 (en)	2012-11-01	Treatment of osteoarthritis and pain
SG178602A1 (en)	2012-04-27	Dual variable domain immunoglobulins and uses thereof
PH12012500774A1 (en)	2012-11-26	Dual variable domain immunoglobulins and uses thereof
PH12012500815A1 (en)	2012-11-26	Dual variable domain immunoglobulins and uses thereof
MX2012004415A (es)	2012-05-08	Inmunoglobulinas de dominio variable doble y usos de las mismas.
MX2012001262A (es)	2012-05-22	Inmunoglobulinas de dominio variable doble y usos de las misma.
MX2011011669A (es)	2011-11-18	Inmunoglobulinas de dominio variable dual y usos de las misma.
MY162511A (en)	2017-06-15	Engineered anti-tslp antibody
EA201590402A1 (ru)	2015-09-30	ЧЕЛОВЕЧЕСКИЕ АНТИТЕЛА ПРОТИВ GFRα3 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
WO2012131555A3 (en)	2012-12-27	Hetero-dimeric immunoglobulins
EA201590247A1 (ru)	2015-10-30	Антитела к siglec-15
WO2012118903A3 (en)	2013-03-14	Sclerostin and dkk-1 bispecific binding agents
EA201490850A1 (ru)	2015-03-31	Состав антитела, пригодный для профилактики и лечения амилоидоза, его варианты и способ его получения
EA202091315A3 (ru)	2021-06-30	Антитела человека, связывающиеся с g-белком rsv
GB201109238D0 (en)	2011-07-13	Antibodies